This inventor holds 2 USPTO granted patents. Top assignees: Aventis Pharma Deutschland, Gmbh, Hoechst Aktiengesellschaft. Active years: 1999-2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 330 
1 out of 6,705 
Years Active: 1999-2001
Title: Frank Buettner: Innovator in Recombinant Substrates
Introduction
Frank Buettner is a notable inventor based in Ludwigshafen, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant substrates for aggrecanase. With a total of 2 patents, his work has implications for understanding and diagnosing osteoarthritis.
Latest Patents
Buettner's latest patents include the invention of an artificial recombinant substrate (rAGG 1) and native aggrecan to determine the proteolytic activity of 'aggrecanase' in cell culture systems. This invention relates to novel recombinant substrates for aggrecanase, which comprise various components such as the signal sequence of CD5, the FLAG-epitope for M1 monoclonal antibody detection, and the interglobular domain of human aggrecan. Additionally, the invention provides DNA sequences encoding the recombinant substrate, vectors, and host cells containing said DNA. Various methods are outlined for monitoring aggrecanase activity, detecting new enzymatic cleavage sites, purifying aggrecanase chromatographically, and screening for aggrecanase inhibitors. A diagnostic aid containing the recombinant substrate is also included in his patents.
Career Highlights
Throughout his career, Frank Buettner has worked with prominent companies in the pharmaceutical and biotechnology sectors. He has been associated with Hoechst Aktiengesellschaft and Aventis Pharma Deutschland GmbH. His experience in these organizations has contributed to his expertise in the field of recombinant technologies.
Collaborations
Some of his notable coworkers include Clare Hughes and Bruce Caterson. Their collaboration has likely enriched the research and development processes in which Buettner has been involved.
Conclusion
Frank Buettner's innovative work in recombinant substrates has the potential to advance the understanding of aggrecanase and its role in osteoarthritis. His contributions to biotechnology are significant and continue to influence the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile